Alimera Sciences, Inc.: Series C $5M

Posted in I - Series C, Q - 3Q09, R - SOUTH EAST, X - Diabetes, X - Opthalmology, XX - GA

Almeria Sciences (Atlanta, GA) a clinical-stage biopharma company focused on ophthalmic disease and treatment of diabetic macular edema, closed a $5M Series C, bringing the total round to $35. Participants have included Polaris Venture Partners, Intersouth Partners, Venrock Associates, Domain Associates and Scale Venture Partners.

Jul

2009

Allostera Pharma, Inc.: Series C $15.4M

Posted in I - Series C, Q - 3Q09, R - INTERNATIONAL, X - Autoimmune, X - Diabetes, X - Gout, X - Psoriatic Arthritis

Allostera Pharma (Canada) a preclinical-stage biopharmaceutical company focused on autoimmune diseases such as psoriatic arthritis, gout and type II diabetes, closed a $15.4M Series C financing. Participants include iNovia Capital, Genesys Capital, BDC Venture Capital and GO Capital.

Jun

2009

Versartis, Inc.: Series A $11M

Posted in I - Series A, Q - 2Q09, R - WEST, X - Diabetes, X - Endocrinology, X - Growth Deficiency, X - Metabolism, XX - CA

Versartis (Redwood City, CA) a preclinical-stage large molecule company focused on diabetes and growth hormone deficiency, closed an $11M Series A financing. Participants include Index Ventures.

Jun

2009

Avid Radiopharmaceuticals, Inc.: Series D $34.5M

Posted in I - Series D, Q - 2Q09, R - NORTH EAST, X - Alzheimer's, X - Dementia, X - Diabetes, X - Imaging, X - Parkinson's, XX - PA

Avid Radiopharmaceuticals (Philadelphia, PA) a development-stage company focused on molecular imaging compounds for diagnostic and detection use in Alzheimer’s, dementia, Parkinson’s and diabetes, closed a $24.5M Series D financing. Participants include Alta Partners, AllianceBernstein, Safeguard Scientifics, Pfizer Venture Investments, Lilly Ventures, RK Ventures Group and BioAdvance.

Jun

2009

Metabolic Solutions Development Co.: Series B $9.3M

Posted in I - Series B, Q - 2Q09, R - MID WEST, X - Diabetes, XX - MI

Metabolic Solutions Development (Kalamazoo, MI) a clinical-stage biopharmaceutical company focused on Type II diabetes, closed a $9.5M Series B financing. Participants include Southwest Michigan First Life Science Fund and Hopen Therapeutics.

Jun

2009

NovImmune, SA: Series C $54.8M

Posted in I - Series C, Q - 2Q09, R - INTERNATIONAL, X - Antibody, X - Diabetes, X - Immunology, X - Inflammation

NovImmune (Switzerland) a clinical-stage biopharmaceutical company focused on therapeutic monoclonal antibodies for inflammatory diseases and immune related disorders, closed a $54.8M series C financing. Participants include BZ Bank Aktiengesellschaft.

May

2009

Elixir Pharmaceuticals, Inc.: Series D $12M

Posted in I - Series D, Q - 2Q09, R - NORTH EAST, X - Diabetes, X - Metabolism, X - Obesity, XX - MA

Elixir Pharmaceuticals (Cambridge, MA) a late-stage pharmaceutical company focused on the treatment of metabolic diseases such as diabetes and obesity, closed a $12M Series D financing. Participants include MPM Capital, Arch Venture Partners, Oxford Bioscience Partners, Omega Funds and Physic Ventures.

Dec

2008

ProteoStasis Therapeutics, Inc.: Series A $45M

Posted in I - Series A, Q - 3Q08, R - NORTH EAST, X - Alzheimer's, X - Diabetes

ProteoStasis Therapeutics (Cambridge, MA) developing therapies to treat multiple genetic and degenerative disorders associated with protein homeostasis deficiencies, closed a $45M Series A financing. Participants include HealthCare Ventures, Fidelity Biosciences, New Enterprise Associates, Novartis Option Fund and Genzyme Ventures.

Dec

2008

InteKrin Therapeutics, Inc.: Series C $20M

Posted in I - Series C, Q - 3Q08, R - WEST, X - Diabetes, X - Metabolism

InteKrin Therapeutics (Los Altos, CA) clinical-stage biopharmaceutical company focused on the development of products for diabetes, metabolism and obesity, closed a $20M Series C financing. Participants include Skyline Ventures, Sofinnova Ventures, OrbiMed Advisors, , Sears Capital Management and Vivo Ventures.

Dec

2008

Dicerna Pharmaceuticals, Inc.: Series A $8.4M

Posted in I - Series A, Q - 3Q08, R - NORTH EAST, X - Diabetes, X - Endocrinology, X - Oncology, X - RNAi

Dicerna Pharmaceuticals (Watertown, MA) clinical-stage biopharmaceutical company developing RNAi therapeutics for multiple clinical applications, closed a $8.4M Series A. Participants include Abingworth, Oxford Bioscience Partners and Skyline Ventures.

« Previous Entries

to top of page...